Anthem Biosciences IPO: issue price, listing date and listing gain

The offer

Anthem Biosciences raised 3,395 crore rupees at an issue price of 570 rupees per share in July 2025, bringing a contract development and manufacturing organisation to the Indian public market. CDMOs, which manufacture active pharmaceutical ingredients and finished formulations for innovator drug companies, are a structural play on the global shift of pharmaceutical outsourcing to India.

Anthem's pitch is built on its integrated CDMO capabilities: it handles drug discovery, development, and commercial manufacturing in a single platform, which is a stickier, higher-margin model than commodity API manufacturing. The company serves global innovators who need a reliable, cost-competitive partner for complex chemistry and biologics.

The issue drew strong institutional interest, with the IPO subscribed 63.86 times overall. That breadth of demand reflects the scarcity of quality, listed CDMO exposure in India at a time when global pharma outsourcing is actively shifting away from single-geography dependence.

The listing and the read

Anthem Biosciences listed on 21 July 2025 at 723.05 rupees on NSE and 723.10 rupees on BSE, a premium of 26.85 percent over the 570 rupee issue price. It was a strong debut for a mid-cap issue in the pharma space, validated by the subscription demand rather than manufactured by thin float.

BazaarBaazi reads a CDMO listing on the quality and stickiness of its customer relationships and the capacity pipeline. A 27 percent day-one premium on a 3,395 crore CDMO issue is the market paying a scarcity premium for integrated, complex-chemistry CDMO exposure. The durability question is whether the margin profile holds as the company scales and whether client concentration creates earnings lumpiness. Editorial framing, not investment advice.

The verified record

The hard, cross-checked facts of the listing.

Listing-day figures are verified against public IPO records. Post-listing prices move daily and are not shown here; this page is the durable record of how Anthem Biosciences came to market, not a live quote.

FAQ4 reader questions · AEO-eligible

Common questions on the Anthem Biosciences IPO.

More from the Class of 2025

How the year's other notable IPOs actually listed.